Complete Conference Management 29th Annual Heart Failure 2025

+ Include: 19 videos + 19 audios + 19 file sub vtt + 21 pdfs, size: 6.7 GB

+ Target Audience: cardiologists, internists, primary care physicians

+ Information:

The 29th Annual Heart Failure 2025 – An Update onTherapy Symposium continues the tradition of providing a comprehensive update on the prevention, diagnosis, and management of heart failure.The program includes lectures presented by experts combined with an opportunity for interactive discussion with faculty. The extensive list of topics has been selected to provide high level and clinically relevant updates on the contemporary approach for the prevention and management of acute and chronic heart failure with the goal of improving clinicians’ knowledge and the care of patients with heart failure of various etiologies.

This year we are offering a Hybrid Event – Attend In-person or Virtually.

PROGRAM OBJECTIVES:

At the conclusion of this activity, the participants should be able to:

1. Provide comprehensive updates on the management of cardiovascular conditions, including new guidelines for hypertension, therapeutic options for hyperlipidemia, and contemporary approaches to heart failure with reduced and preserved ejection fraction.
2. Review advanced treatment strategies for complex cardiovascular scenarios, including acute decompensated heart failure, heart failure with kidney disease, atrial fibrillation in heart failure patients, and catheter-based interventions for valvular heart disease.
3. Discuss specialized management approaches for specific cardiovascular conditions, including heart failure due to hypertrophic cardiomyopathy and amyloidosis, obesity in heart failure patients, and pulmonary arterial hypertension.

TARGET AUDIENCE
This program has been designed to provide cardiologists, internists, primary care physicians, pharmacists, nurses and other healthcare providers with the necessary information to increase knowledge with the goal of improving the care of patients with HF.

+ Topics:

• 7:00-8:00am Registration/Visit Exhibits
• 7:45-8:45 ProductTheatre I – Breakfast – Non-CME hATTR Progression: Addressing Polyneuropathy Supported by: AstraZeneca Speaker: DmitryYaranov, MD
• 8:45-8:55 Introduction to the 29th Annual Symposium: Heart Failure 2025 – An Update on Therapy Uri Elkayam, MD
• SESSION I 8:55-9:15 Hyperlipidemia: An Update on Non-Statin Therapy PamTaub, MD
• 9:15- 9:35 Evolving Strategies for the Management of Hypertrophic Cardiomyopathy: Cardiac Myosin Inhibitors,When and How to UseThem Michelle M. Kittleson, MD
• 9:35-9:55 Treating Congestion and Optimizing GDMP in the Hospitalized Patient with ADHF Maria Rosa Costanzo, MD
• 9:55-10:15 Contemporary DrugTherapy for Patients with Heart Failure and Reduced Ejection Fraction Akshay Desai, MD
• 10:15-10:35 Visit Exhibits/Break
• SESSION II 10:35-11:00 KEYNOTE LECTURE Advances In GeneTherapy ForTreating PatientsWith Cardiomyopathy Barry Greenberg, MD
• 11:00-11:20 How Do I Optimize Heart Failure Medications for Patients with Chronic and End Stage Kidney Disease? Maria Rosa Costanzo, MD
• 11:20-11:40 The Contemporary Approach to the Management of Cardiogenic Shock Nir Uriel, MD
• 11:40-11:55 HFpEF: Diagnostic Challenges and Pitfalls Uri Elkayam, MD
• 11:55-12:15 Advances in Pharmacologic and Nonpharmacological Management of HFpEF Akshay Desai, MD
• 12:15-1:15 ProductTheatre II – Luncheon – Non-CME Introduction to AMVUTTRA® (vutrisiran) Supported by: Alnylam Pharmaceuticals Speaker: Marcus Anthony Urey, MD
• 1:15-1:20 Break
• 1:20-1:50 Industry Session – Non-CME Rethinking Hyperkalemia Management in Patients on RAAS InhibitorTherapy Supported by: AstraZeneca Speaker: Ashish Brahmbhatt, PharmD
• 1:50-1:55 Break
• SESSION III 1:55-2:15 Closing the Knowledge Gap On Diagnosis AndTreatment Of Implantable Cardiac Device Infection In Heart Failure Ulrika Birgersdotter-Green, MD
• 2:15-2:35 Tricuspid Regurgitation: Prevalence, Prognostic Implications and Emerging Therapy Steven Burstein, MD
• 2:35-2:55 Management of Atrial Fibrillation in Patients Across the Spectrum of Heart Failure Anil Bhandari, MD
• 2:55-3:15 Anti-Obesity Medications in Patients with Heart Failure: Current Evidence and Practical Guidance Amanda R. Vest, MBBS, MPH
• 3:15-3:35 Break/Visit Exhibits
• SESSION IV 3:35-3:50 Beyond MedicalTherapy – Carotid Baroreceptor Stimulation and Cardiac Contractility Modulation Michael Fong, MD
• 3:50-4:10 Finerenone – A New Option for the Management of Heart Failure and Kidney Disease: Results of ClinicalTrials and Implications forTherapy Uri Elkayam, MD
• 4:10-4:30 What is New in the Management of Hypertension – Review of the 2024 ESC Guidelines Vito Campese, MD
• 4:30-4:50 ATTR Amyloidosis: Current and Emerging Management Strategies Mazen Hanna, MD
• 4:50-5:10 Pulmonary Arterial Hypertension: Introduction of NewTherapy Ron Oudiz, MD
• 5:10-5:30 The Potential Use Of AI InThe Diagnosis And Management Of Heart Failure Nir Uriel, MD
• 5:30pm Adjourn